Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telitacicept for refractory systemic lupus erythematosus in children
ChiCTR2500108467Phase 4Not yet recruiting
- Sponsor
- Beijing Children's Hospital
- Start
- Sep 2025
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of telitacicept in systemic lupus erythematosus (SLE), sponsored by Beijing Children's Hospital. Primary endpoint: SLE Responder Index-4 (SRI-4) response. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
telitacicept
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on ChiCTR2500108467.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500108467.